Atlas Trials

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Clinical trial NCT05024097 · RECRUITING

Trial details

NCT number
NCT05024097
Sponsor
Weill Medical College of Cornell University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Rectal Cancer
Start date
2022-03-31
Primary completion
2026-12-01
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.